Scarica l'app Stockscreener
808.11
0.56%
-4.58
Dopo l'orario di chiusura:
808.62
0.51
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$812.69
Aprire:
$812.65
Volume 24 ore:
2.59M
Relative Volume:
0.70
Capitalizzazione di mercato:
$765.87B
Reddito:
$49.00B
Utile/perdita netta:
$11.11B
Rapporto P/E:
65.75
EPS:
12.29
Flusso di cassa netto:
$-1.27B
1 W Prestazione:
+6.03%
1M Prestazione:
+4.21%
6M Prestazione:
+0.39%
1 anno Prestazione:
+0.43%
Intervallo 1D:
$802.50
$820.22
Intervallo di 1 settimana:
$762.50
$820.22
Portata 52W:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
808.11 | 729.58B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
166.22 | 405.32B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
188.52 | 336.11B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
116.18 | 227.85B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
69.00 | 318.59B | 43.59B | 15.04B | 10.74B | 3.3766 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly Alleges Pharmacy Sells Knockoff Weight-Loss Drugs - Law360
Eli Lilly refiles complaint against Empower Pharmacy over compounded drugs in Texas federal court - The Business Journals
Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY) - Insider Monkey
Eli Lilly & Co: Buy Rating Backed by Promising Clinical Trials and Strong Financial Outlook - TipRanks
Eli Lilly (LLY) CEO’s Pay Nears $30 Million - TipRanks
Eli Lilly and Company Acquires Vere Therapeutics to Further Develop One-Time Cardiovascular Treatments - PharmExec
Morgan Stanley Remains Bullish on Eli Lilly (LLY) - Insider Monkey
Eli Lilly’s (LLY) Kisunla Gets FDA Approval for Safer Alzheimer’s Dosing Schedule - Insider Monkey
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales - Insider Monkey
Leerink Partners and Jefferies Issue Bullish Ratings on Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment - Yahoo.co
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might - The Motley Fool
Eli Lilly, McDonald’s, Marvell, Delta, RTX: Insider Sales Shake Market - TipRanks
Eli Lilly Stock Price Today | NYSE LLY - Investing.com Canada
Eli Lilly (LLY) Gains EU Panel Support for Alzheimer's Drug - GuruFocus
Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines - BioSpace
Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily
EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection - Reuters
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel - Benzinga
Eli Lilly (LLY) Completes Acquisition of Verve Therapeutics | LL - GuruFocus
Lilly Completes Acquisition Of Verve Therapeutics - Nasdaq
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company - Eli Lilly and Company
Lilly Acquires Verve Therapeutics, Targets One-Time Cardiovascular Treatment | LLY Stock News - Stock Titan
Lilly Gets Limited European Backing for Alzheimer’s Drug - Bloomberg.com
Eli Lilly (LLY) Awaits European Approval for Alzheimer's Drug | - GuruFocus
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease - Eli Lilly and Company
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines - BioSpace
Eli Lilly and Company India launches ‘We Know Now’ obesity awareness campaign - MediaBrief
Eli Lilly's Trademark Suit Not 'Abuse Of Process' - Law360
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines - Business Wire
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings? - The Globe and Mail
The 3 Things That Matter for Eli Lilly Now - AOL.com
Lilly confirms date and conference call for second-quarter 2025 financial results announcement - Eli Lilly and Company
Eli Lilly Q2 2025 Earnings Call: Key Date and Details Investors Should Know - Stock Titan
Lilly completes tender offer for Verve Therapeutics shares By Investing.com - Investing.com Nigeria
Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly and Company
Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan
Eli Lilly targets golden goose with Mounjaro launch in Korea amidst competitionCHOSUNBIZ - Chosunbiz
Tariffs Weigh on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks
Eli Lilly, GE Vernova Surge Among Wednesday’s Market Cap Stock Movers - Investing.com Canada
Eli Lilly’s Phase 3 Breast Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly’s LY3971297 Study: A Potential Game-Changer in Obesity and Hypertension Treatment - TipRanks
Eli Lilly’s Baricitinib Study: A Potential Game-Changer for Juvenile Arthritis - TipRanks
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - Insider Monkey
Jim Cramer on Eli Lilly: “It Needs Breakthroughs in New Areas” - Insider Monkey
Earnings Preview: What To Expect From Eli Lilly's Report - Barchart.com
Eli Lilly (LLY) Collaborates on Alzheimer's Diagnostic Test with CE Mark Approval | LLY Stock News - GuruFocus
Lilly to launch Mounjaro in Korea in August without reimbursement - koreabiomed.com
BMO Capital Pounds the Table on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks
BMO Capital reiterates Eli Lilly stock rating with $900 price target By Investing.com - Investing.com South Africa
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):